BOONTON, N.J., Dec. 3, 2013 /PRNewswire/ -- Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, today announced the appointment of Steven J. Brickner, Ph.D., Jonathan Chernoff, MD, Ph.D., and Waleed Danho, Ph.D to the company's Scientific Advisory Board.
Highly regarded scientists and thought leaders, Drs. Brickner, Chernoff and Danho will work with Enteris' executive team to maximize the potential of its proprietary oral delivery technology platform and the development of orally delivered peptide and small molecule drugs.
Brian Zietsman, President and CFO of Enteris BioPharma, commented, "We are very honored to welcome such esteemed scientific minds as Drs. Brickner, Chernoff and Danho to our inaugural Scientific Advisory Board. Already in the short time that Drs. Brickner, Chernoff and Danho have been advising our company and working with our proprietary oral delivery technology platform, they have provided invaluable input on potential development opportunities and therapeutic targets. We greatly look forward to benefitting from their unparalleled acumen as Enteris seeks to become the industry leader in the oral delivery of peptides and difficult to deliver small molecule therapeutics."
With more than 100 combined years of industry and research experience, Drs. Brickner, Chernoff and Danho each offers areas of specialization that will help to shape Enteris' development strategy and therapeutic pursuits.
Dr. Brickner joins Enteris' Scientific Advisory Board as an expert in synthetic organic/medicinal chemistry and the discovery of novel antibacterial agents. While at Upjohn, Dr. Brickner was the co-inventor of Zyvox® (linezolid), an oxazolidinone that holds the #1 rank among all
|SOURCE Enteris BioPharma, Inc.|
Copyright©2012 PR Newswire.
All rights reserved